Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors

Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, Becker JC, Submitter AD, Doener F, Heidenreich R, Scheel B, Schoenborn-Kellenberger O, Seibel T, Gnad-Vogt U (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 466-466

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich DE

DOI: 10.1093/annonc/mdy289.061

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Elbe Kliniken Stade-Buxtehude DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) CureVac GmbH DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Cogitars GmbH DE Germany (DE)

How to cite

APA:

Terheyden, P., Weishaupt, C., Heinzerling, L., Klinkhardt, U., Krauss, J., Mohr, P.,... Gnad-Vogt, U. (2018). Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors. In ANNALS OF ONCOLOGY (pp. 466-466). Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Terheyden, P., et al. "Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018. 466-466.

BibTeX: Download